SCHEMBL14361997

SCHEMBL14361997

NNC(=O)c1ccncc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 16/20 0.56
KDM6B O15054 8/20 0.56
KDM4D Q6B0I6 5/20 0.56
KDM4E B2RXH2 4/20 0.56
KDM4A O75164 2/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
MEN1 O00255 1/20 0.56
THRB P10828 1/20 0.56
KMT2A Q03164 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MPO P05164 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2A6 P11509 1/20 0.50
CYP2C19 P33261 1/20 0.50
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL894396 0.93 KDM4C (0.56) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL13518160 0.90 KDM4E (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL29416303 0.82 KDM4C (0.65) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL71335 0.82 KDM4C (0.65) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL28799175 0.80 KDM4C (0.63) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL19857493 0.80 KDM4C (0.63) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL27758655 0.80 KDM4C (0.63) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL26607910 0.80 KDM4C (0.63) KDM4CKDM6BKDM4DKDM4EKDM4A
Hydrochloric Acid SCHEMBL10697489 0.80 KDM4C (0.63) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL15713099 0.79 KDM4E (0.52) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723744-B1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2016-03-23 EP disclosed
US-20140147386-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
EP-2723744-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2014-04-30 EP disclosed
WO-2013000924-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140147386-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES PDE2A, PDE12, PDE5A KDM4C 459/4885KDM6B 469/4885KDM4D 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.